Blood tests and brain scans can now show signs of Alzheimer's up to 20 years before symptoms appear. So what can we do with that head start? Meryl Comer talks with Dr. Frank Longo, Stanford neurologist and founder and board chairman of PharmatrophiX. Dr. Longo’s work shifts the question from how to clear amyloid that has built up in the brain to how to prevent pathological tau from building up and at the same time keeping the brain's communication network strong enough to withstand damage in the first place. They discuss an oral drug that targets a key receptor for brain connection integrity, its early trial results, and what it would take to make Alzheimer’s prevention affordable and reachable for everyone. This educational episode shows the progress made in Alzheimer’s research and provides hope for the future. You don’t want to miss this!
Podden och tillhörande omslagsbild på den här sidan tillhör
Meryl Comer, UsAgainstAlzheimer's. Innehållet i podden är skapat av Meryl Comer, UsAgainstAlzheimer's och inte av,
eller tillsammans med, Poddtoppen.